Unveiling the first GIP and GLP-1 medication for Chronic Weight Management and Type 2 Diabetes

Introduction

Take This Event

Learn about the obesity as a chronic disease, the role of GIP and GLP-1 in obesity and type 2 diabetes and the mechanism of action of Mounjaro as first-in-class medication for chronic weight management and type 2 diabetes.

Objectives

-Learn about obesity as a chronic disease which is a public health issue across the globe and specially in KSA
-Better understanding of the Pathophysiology of T2D/obesity, the related metabolic adaption and the role of GIP and GLP-1 receptors.
-Unveiling the mechanism of action of Mounjaro as the first-and-only treatment activating both the GIP and GLP-1 receptors to treat T2D and chronic weigh management.
-Understand the data from the clinical trials related to efficacy and safety of Mounjaro in T2D and chronic weigh management.

Speaker

Dr. Abdullah Al-Zahrani

Consultant Family Medicine & Diabetologist
Associate Professor of Family Medicine, COM,KSUHS
Member of European Society of Hypertension (ESH)

Dr. Hussein Badawy

Consultant Endocrinologist
American Board of Obesity Medicine
Chairman of Metabolic Unit, MyClinic ,Jeddah

Dr. Ashraf Ameeri

Consultant Family Medicine
Chief executive for executive health programs
Vice president of the Saudi Society of Family and Community Medicine